Tags : Acceleron

PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)

1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106 Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates 2. Innate’s Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA’s MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemia Published: Jan 03, 2019 | Tags: EMA, Hairy Cell Leukemia, Innate, Lumoxit, MAA, […]Read More

Acceleron Signs a License Agreement with Fulcrum for the Identification

Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional payments $143.5M for all subsequent products commercialized plus royalties on sales of product Acceleron to get rights to access Fulcrum’s product engine and target identification platform for identifying small molecule […]Read More

PharmaShots Weekly Snapshot (September 16– 20, 2019)

1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. Astellas and FibroGen’s Evrenzo (roxadustat) Receives MHLW’s Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients Published: Sept 20, 2019 | Tags: Astellas, FibroGen, […]Read More

Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to

Shots: The BLA submission is based on P-III MEDALIST & BELIEVE studies. The P-III MEDALIST study involves assessing of luspatercept (1.0 mg/kg) vs PBO in 229 patients with low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia + RBC transfusion aged ~71yrs across 11 countries The P-III BELIEVE study involves assessing of luspatercept (1.0 mg/kg) + […]Read More